<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02137538</url>
  </required_header>
  <id_info>
    <org_study_id>AI growth study</org_study_id>
    <nct_id>NCT02137538</nct_id>
  </id_info>
  <brief_title>Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole</brief_title>
  <official_title>Randomization to Letrozole vs. Anastrozole in Short Pubertal Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if there are differences in the final height or&#xD;
      hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now&#xD;
      routinely used to increase stature: Anastrozole and Letrozole. It also should determine if&#xD;
      there are differences in the side effect profiles of the two drugs to be used.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2009</start_date>
  <completion_date type="Actual">June 5, 2018</completion_date>
  <primary_completion_date type="Actual">June 5, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Predicted Adult Height at Year 3</measure>
    <time_frame>Year 3</time_frame>
    <description>Heights will be obtained by physical exam every 6 months during treatment. Skeletal maturation will be assessed from an x-ray by the method of Greulich and Pyle at baseline and every 12 months until the end of treatment.&#xD;
Predicted adult height will be calculated at baseline and at the end of treatment based upon measured height and skeletal maturation (bone age).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Testosterone</measure>
    <time_frame>Baseline, year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dihydrotestosterone</measure>
    <time_frame>Baseline, year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androstenedione</measure>
    <time_frame>Baseline, year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteinizing Hormone</measure>
    <time_frame>Baseline, year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle Stimulating Hormone</measure>
    <time_frame>Baseline, year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin-like Growth Factor Type 1</measure>
    <time_frame>Baseline, year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibin B</measure>
    <time_frame>Baseline, year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol</measure>
    <time_frame>Baseline, year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estrone</measure>
    <time_frame>Baseline, year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events Related to Acne or Bone Fracture</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Short Stature</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Letrozole 2.5 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anastrozole 1 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <arm_group_label>Anastrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current height less than 5th percentile AND/OR&#xD;
&#xD;
          -  Predicted adult height (based on bone age) more than 10 cm below target height (mid&#xD;
             parental height)&#xD;
&#xD;
          -  Evidence of puberty: physical signs and serum luteinizing hormone &gt; 0.3 IU/L and&#xD;
             testosterone &gt; 15 ng/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bone age reading more than 14.0 years&#xD;
&#xD;
          -  Follicle stimulating hormone &gt; 20 IU/L&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E Kirk Neely, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura K Bachrach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter A Zegarra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Neely EK, Kumar RB, Payne SL, Ranadive SA, Suchet DI. Letrozole vs anastrozole for height augmentation in short pubertal males: first year data. J Clin Endocrinol Metab. 2014 Nov;99(11):4086-93. doi: 10.1210/jc.2014-2432. Epub 2014 Aug 19.</citation>
    <PMID>25137428</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 5, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2014</study_first_posted>
  <results_first_submitted>June 24, 2021</results_first_submitted>
  <results_first_submitted_qc>June 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2021</results_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Laura K Bachrach</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02137538/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 24, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02137538/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Letrozole</title>
          <description>Participants receive letrozole 2.5 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Anastrozole</title>
          <description>Participants receive anastrozole 1 mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
      <group_list>
        <group group_id="B1">
          <title>Letrozole</title>
          <description>Participants receive letrozole 2.5 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Anastrozole</title>
          <description>Participants receive anastrozole 1 mg daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.9" spread="1.2"/>
                    <measurement group_id="B2" value="13.9" spread="1.5"/>
                    <measurement group_id="B3" value="13.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156.1" spread="6.6"/>
                    <measurement group_id="B2" value="156.3" spread="12.2"/>
                    <measurement group_id="B3" value="156.2" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Predicted Adult Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.2" spread="5.8"/>
                    <measurement group_id="B2" value="167.3" spread="6.9"/>
                    <measurement group_id="B3" value="167.2" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Predicted Adult Height at Year 3</title>
        <description>Heights will be obtained by physical exam every 6 months during treatment. Skeletal maturation will be assessed from an x-ray by the method of Greulich and Pyle at baseline and every 12 months until the end of treatment.&#xD;
Predicted adult height will be calculated at baseline and at the end of treatment based upon measured height and skeletal maturation (bone age).</description>
        <time_frame>Year 3</time_frame>
        <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Participants receive letrozole 2.5 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Participants receive anastrozole 1 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Predicted Adult Height at Year 3</title>
          <description>Heights will be obtained by physical exam every 6 months during treatment. Skeletal maturation will be assessed from an x-ray by the method of Greulich and Pyle at baseline and every 12 months until the end of treatment.&#xD;
Predicted adult height will be calculated at baseline and at the end of treatment based upon measured height and skeletal maturation (bone age).</description>
          <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.8" spread="5.8"/>
                    <measurement group_id="O2" value="169.4" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Testosterone</title>
        <time_frame>Baseline, year 3</time_frame>
        <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Participants receive letrozole 2.5 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Participants receive anastrozole 1 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Testosterone</title>
          <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213.1" spread="133.7"/>
                    <measurement group_id="O2" value="162.1" spread="124.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="882.3" spread="250.5"/>
                    <measurement group_id="O2" value="680.1" spread="179.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dihydrotestosterone</title>
        <time_frame>Baseline, year 3</time_frame>
        <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Participants receive letrozole 2.5 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Participants receive anastrozole 1 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Dihydrotestosterone</title>
          <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="11.3"/>
                    <measurement group_id="O2" value="19.1" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" spread="20.2"/>
                    <measurement group_id="O2" value="44.1" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Androstenedione</title>
        <time_frame>Baseline, year 3</time_frame>
        <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Participants receive letrozole 2.5 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Participants receive anastrozole 1 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Androstenedione</title>
          <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" spread="13.1"/>
                    <measurement group_id="O2" value="37.4" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" spread="21.5"/>
                    <measurement group_id="O2" value="77.9" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Luteinizing Hormone</title>
        <time_frame>Baseline, year 3</time_frame>
        <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Participants receive letrozole 2.5 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Participants receive anastrozole 1 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Luteinizing Hormone</title>
          <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.5"/>
                    <measurement group_id="O2" value="1.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.9"/>
                    <measurement group_id="O2" value="3.4" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Follicle Stimulating Hormone</title>
        <time_frame>Baseline, year 3</time_frame>
        <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Participants receive letrozole 2.5 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Participants receive anastrozole 1 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Follicle Stimulating Hormone</title>
          <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.9"/>
                    <measurement group_id="O2" value="2.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="2.4"/>
                    <measurement group_id="O2" value="4.5" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin-like Growth Factor Type 1</title>
        <time_frame>Baseline, year 3</time_frame>
        <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Participants receive letrozole 2.5 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Participants receive anastrozole 1 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-like Growth Factor Type 1</title>
          <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.2" spread="112.8"/>
                    <measurement group_id="O2" value="306.9" spread="112.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226.1" spread="54.4"/>
                    <measurement group_id="O2" value="298.7" spread="78.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inhibin B</title>
        <time_frame>Baseline, year 3</time_frame>
        <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Participants receive letrozole 2.5 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Participants receive anastrozole 1 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibin B</title>
          <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.4" spread="55.0"/>
                    <measurement group_id="O2" value="217.0" spread="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257.6" spread="61.1"/>
                    <measurement group_id="O2" value="262.1" spread="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estradiol</title>
        <time_frame>Baseline, year 3</time_frame>
        <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Participants receive letrozole 2.5 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Participants receive anastrozole 1 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estradiol</title>
          <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="3.6"/>
                    <measurement group_id="O2" value="4.7" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="2.1"/>
                    <measurement group_id="O2" value="6.2" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estrone</title>
        <time_frame>Baseline, year 3</time_frame>
        <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Participants receive letrozole 2.5 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Participants receive anastrozole 1 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estrone</title>
          <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="4.8"/>
                    <measurement group_id="O2" value="8.0" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.3"/>
                    <measurement group_id="O2" value="3.5" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events Related to Acne or Bone Fracture</title>
        <time_frame>3 years</time_frame>
        <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
        <group_list>
          <group group_id="O1">
            <title>Letrozole</title>
            <description>Participants receive letrozole 2.5 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Participants receive anastrozole 1 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events Related to Acne or Bone Fracture</title>
          <population>Participants who finished the first year of therapy are included in the analysis, excluding participants who had received growth hormone.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acne</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Letrozole</title>
          <description>Participants receive letrozole 2.5 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Anastrozole</title>
          <description>Participants receive anastrozole 1 mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <description>Unexpected serious adverse event; significant but not persistent.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuro event</sub_title>
                <description>Unexpected serious adverse event; significant but not persistent.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>E Kirk Neely</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-5791</phone>
      <email>neely@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

